Trending Market News

UniCredit will not attend Commerzbank's annual shareholder meeting on Wednesday, maintaining a passive stance despite its ongoing takeover battle for the German lender. The decision comes at a critical point in the months-long dispute between UniCredit, which seeks control, and Commerzbank, which wants to remain independent.

• UniCredit CEO Andrea Orcel had previously stated in April that the bank had not decided on participation in the meeting
• The annual meeting occurs during a pivotal moment in the takeover tussle between the Italian and German lenders
• UniCredit declined to comment on its decision to skip the shareholder meeting

Shinsegae Group fired the CEO of Starbucks Korea after a promotional campaign called 'Tank Day' sparked public outrage by coinciding with the anniversary of the 1980 Gwangju pro-democracy uprising. The promotion's wording was seen as insensitive to victims of military violence during South Korea's fight against dictatorship, prompting an apology and swift executive action.

• The 'Tank Day' promotion launched on Democratisation Movement Day, the anniversary of the May 18, 1980 Gwangju uprising where hundreds or thousands were killed by military dictator Chun Doo-hwan's forces
• The campaign's wording recalled a former official's explanation for the 1987 death of a student protester later found to have been tortured, drawing connections to South Korea's authoritarian past
• South Korean President Lee Jae Myung publicly expressed being 'enraged' and demanded the company apologize to families of those killed during the uprising

Japan's economy grew at an annualized rate of 2.1% in Q1 2026, beating analyst expectations of 1.7% and improving from the previous quarter's 1.3% growth. The stronger-than-expected performance comes as the Bank of Japan has cut its full-year growth forecast and raised inflation projections due to rising crude oil prices from Middle East conflicts.

• Quarter-on-quarter growth was 0.5%, exceeding the 0.4% estimate and improving from 0.3% at the end of 2025
• The Bank of Japan cut its fiscal 2026 growth forecast to 0.5% from 1% while raising core inflation outlook to 2.8% from 1.9%, citing crude oil price increases
• The Q1 figures do not capture the full impact of the Iran war that began in late February, with economists warning of a potential 'stagflation-like situation' as real disposable incomes remain negative

Google I/O begins Tuesday as Alphabet seeks to demonstrate its AI leadership across the full technology stack, from custom chips to cloud infrastructure to consumer products. The company's stock has surged 140% over the past year, with cloud revenue growing 63% year-over-year and surpassing Azure and AWS growth rates. Investors are watching for updates on the next Gemini model, AI agents, agentic commerce, and external TPU chip sales.

• Google Cloud backlog reached $462 billion, up roughly 90% quarter-over-quarter, with generative AI product revenue growing approximately 800% year-over-year and the number of billion-dollar-plus deals in 2025 exceeding the previous three years combined.
• A potential Gemini 4 model announcement would position Google 'back up to the bleeding edge' against OpenAI and Anthropic, though analysts consider a Gemini 3.2 or 3.5 update more likely given the company's three-to-four month release cadence.
• Google plans to begin delivering its custom TPU AI chips to external customers in second half 2026, creating a new revenue stream in the estimated $500 billion AI chip market, while its $200 billion cloud commitment from Anthropic represents a significant portion of future contracted revenue.

U.S. crude oil futures dropped more than 2% in early Asian trading on Tuesday after President Trump paused a planned military strike on Iran to allow time for negotiations to end conflict in the Middle East. The decline reversed gains from the previous session as geopolitical tensions temporarily eased.

• WTI July contract fell $2.08 (2.02%) to $102.34 per barrel, while the front-month June contract dropped $1.54 (1.42%) to $107.12
• The decline followed Trump's announcement of pausing an Iran strike in favor of diplomatic negotiations
• Oil had gained over 3.1% in the previous session, suggesting markets had priced in heightened Middle East conflict risk

Germany's finance ministry has initiated a sales process for Uniper, the energy company nationalized during the 2022 European energy crisis, aiming to reduce the government's 99.12% stake to 25% plus one share. Interested parties have until June 12 to express interest. The sale or listing process is expected to be formalized before summer.

• Germany currently holds a 99.12% stake in Uniper after nationalizing the company during the 2022 energy crisis
• The sales process targets reducing government ownership to just 25% plus one share, with expressions of interest due by June 12
• The divestment will likely result in either a direct sale or public listing of the bailed-out energy firm

Bayer's Monsanto unit will pay at least $133 million to settle claims from Michigan and Rhode Island over PCB contamination of state natural resources. This brings Bayer's total PCB settlements to a dozen U.S. states as the company addresses legacy liabilities from chemicals Monsanto produced from 1935 to 1977. The settlement includes no admission of wrongdoing and could increase if Bayer succeeds in its lawsuit against former PCB buyers for indemnification.

• Michigan receives at least $108 million and Rhode Island at least $25 million, with potential additional payments of up to $176 million and $50 million respectively if Bayer wins its indemnification lawsuit against six legacy PCB buyers
• PCBs were widely used in electrical equipment, paper, caulking, and paint until banned by the U.S. government in 1979 due to links to cancer and other health problems
• Bayer acquired Monsanto for $63 billion in 2018 and has since faced extensive litigation over both PCBs and Roundup weedkiller claims across municipalities, states, schools, and individuals

French drugmaker Sanofi announced that its experimental rare disease therapy, efdoralprin alfa, outperformed standard care in a 97-patient trial for a genetic lung disease, raising key protein levels more effectively. The therapy, acquired through Sanofi's $2.2 billion Inhibrx deal in 2024, offers less frequent dosing and could help the company diversify beyond its top-selling drug Dupixent. Sanofi estimates about 235,000 people have the condition and sees opportunity in switching patients and reaching undiagnosed individuals.

• Efdoralprin alfa raised AAT protein levels by 24.1 micromolar at week 32 versus 7.6 micromolar for weekly standard therapy, with patients maintaining normal AAT levels throughout the study
• The therapy requires dosing only every three weeks compared to weekly for standard plasma-derived treatments, potentially easing treatment burden on patients
• Sanofi acquired the drug through its 2024 Inhibrx deal worth $2.2 billion following pipeline setbacks, as investors seek growth drivers beyond Dupixent

A U.S. jury ruled that Takeda Pharmaceutical caused approximately $885 million in damages to pharmacies, insurers, retailers, and other parties by delaying the release of a generic version of its constipation drug Amitiza through an anticompetitive scheme.

• The verdict holds Takeda liable for $885 million in damages across multiple affected parties including pharmacies, insurers, and retailers
• The case centered on allegations that Takeda engaged in an antitrust scheme to delay generic competition for Amitiza, its anti-constipation medication
• The jury's finding represents a significant legal loss for the Japanese pharmaceutical company in a U.S. antitrust case

Volvo Group will take a $197 million charge in Q2 2025 to settle allegations from California Air Resources Board regarding inadequate emission control descriptions on truck engines sold in California between 2010-2016. The settlement includes penalties, environmental project spending, and software updates for approximately 7,200 engines, with no admission of liability from Volvo.

• The settlement breaks down as: $13 million in civil penalties, $71 million to California's Air Pollution Control Fund, $108 million for emissions-reduction projects, and $5 million for CARB cost reimbursement
• Volvo will provide software updates and partial warranty extensions for about 7,200 affected engines in California as part of the agreement
• Operating cash-flow impact will be $89 million in the current quarter, with remaining payments spread over five years; the charge will be excluded from adjusted operating income

President Trump will announce a major expansion of TrumpRx.gov on Monday, adding generic medications to the government-backed discount drug website. Billionaire Mark Cuban, who runs Cost Plus Drugs online pharmacy, is expected to attend the White House event. The expansion is part of Trump's most-favored-nation deals with drugmakers aimed at lowering U.S. prescription costs to match other developed nations.

• TrumpRx.gov was originally launched in January as part of pricing agreements with pharmaceutical companies to reduce drug costs
• Despite Trump's pledge to make prescription drugs cheaper in the U.S. than anywhere else, a Reuters analysis found prices on the website are not lower than those in the United Kingdom
• Mark Cuban's Cost Plus Drugs, which already sells discounted medicines directly to consumers, will apparently play a role in the expanded program

BYD launched an upgraded version of its Denza N9 flagship SUV with a 5% price increase to 409,800 yuan ($60,265), marking the Chinese EV maker's continued push into premium markets and away from its low-cost image. The move comes as Denza faces intensifying competition from domestic rivals, with retail sales down 41.5% in the first four months of 2026 compared to the prior year. BYD is positioning Denza as key to its high-margin export strategy, having recently introduced the brand in Europe with actor Daniel Craig as brand ambassador.

• The new Denza N9 features over 100 upgrades including extended battery range and fast-charging capability, with a starting price of 409,800 yuan, up from 389,900 yuan for the previous model launched 14 months ago
• Denza claims 70% of its D9 buyers were former BMW, Mercedes-Benz, or Audi owners in China, though overall retail sales slumped 41.5% year-over-year in early 2026 due to competition from brands like Zeekr and Voyah
• BYD gained full ownership of Denza after Mercedes-Benz exited the joint venture in 2024, and is now betting on the premium brand to drive its high-margin export strategy in markets like Europe

Roche and the UN-backed Medicines Patent Pool signed a licensing agreement to expand access to flu drug Xofluza across 129 low- and middle-income countries. The deal allows generic manufacturers to produce the antiviral pill, aiming to boost supply during seasonal outbreaks and potential pandemics in regions with limited access to flu medicines.

• Generic drugmakers can now develop, manufacture and supply Xofluza across 129 low- and middle-income countries under the licensing agreement
• Xofluza is WHO-recommended and approved in the US and Europe, showing effectiveness against flu strains resistant to older antiviral classes
• Roche will provide licenses with data packages, reference products and regulatory support to accelerate generic development, while manufacturers handle their own approval processes

Uber Technologies has increased its ownership stake in Germany's Delivery Hero, according to an announcement made by Delivery Hero on Monday. The move strengthens Uber's position in the European food delivery market through its investment in one of the region's major players.

• Delivery Hero, a major German food delivery company, confirmed Uber has purchased additional shares
• The transaction reinforces Uber's strategic interests in international delivery markets beyond its core ride-hailing business
• This follows related news of Uber partnering with Naver on a potential Baemin takeover in South Korea

The U.S. Supreme Court on May 18 declined to hear challenges from six major pharmaceutical companies against Medicare's drug price negotiation program, which was established under Biden's 2022 Inflation Reduction Act. The decision leaves intact lower court rulings that rejected drugmakers' constitutional claims, allowing the program to continue under the Trump administration's defense.

• Six companies (Novo Nordisk, AstraZeneca, Janssen, Bristol Myers Squibb, Novartis, and Boehringer Ingelheim) had argued the program violates constitutional rights including Fifth Amendment protections and First Amendment free speech guarantees
• The first negotiated prices on 10 drugs went into effect in 2026, with the program requiring drugmakers to negotiate maximum prices with CMS or face steep daily excise taxes and potential withdrawal from Medicare programs
• The Trump administration is continuing to defend the Biden-era mechanism, with CMS Administrator Mehmet Oz citing it as part of efforts to reduce prescription drug costs for Medicare beneficiaries

The Supreme Court declined to hear Eli Lilly's challenge to the False Claims Act, a Civil War-era whistleblower law, leaving intact a $183 million judgment against the drugmaker for defrauding Medicaid. Lilly had argued the law unconstitutionally gives executive power to private citizens who can sue on behalf of the government. The decision preserves a law that recovered over $6.8 billion for the government in fiscal 2025.

• A federal jury found Lilly knowingly concealed retroactive drug price increases and failed to rebate Medicaid, resulting in $61 million in damages automatically tripled to $183 million under the False Claims Act
• The government recovered more than $6.8 billion through False Claims Act cases in fiscal 2025, with whistleblowers awarded over $330 million
• Lilly argued the law violates the Constitution by placing 'executive authority in the hands of private citizens with no meaningful supervision,' turning 'bounty hunters into ersatz executive officers'

Lululemon is publicly confronting founder Chip Wilson after settlement talks collapsed, calling his criticism 'misguided' and 'outdated' in a letter to shareholders. Wilson has been campaigning to replace board members, arguing the company has deprioritized creative excellence, while Lululemon defends its leadership and strategy. The dispute will come to a head at next month's annual meeting where shareholders will choose between the company's board nominees and Wilson's three candidates.

• Settlement talks broke down after Lululemon offered to appoint two of Wilson's nominees (up from one), but Wilson demanded additional concessions including director replacement rights and full campaign reimbursement
• Lululemon's stock has fallen significantly as the company faces pressure from tariffs, weak U.S. consumer demand, and increased competition from brands like Vuori and Alo Yoga that Wilson has advised
• The company is defending incoming CEO Heidi O'Neill, a nearly 30-year Nike veteran set to start in September, highlighting her experience building Nike's multi-billion-dollar women's business and leading digital transformation

China's solar cell exports surged 60% year-over-year in April 2025, reaching $3.12 billion in value despite the government's cancellation of an export tax refund program on April 1. The strong growth was driven by rising demand in Southeast Asia and Africa, though monthly volumes declined from March's peak.

• April exports totaled 1.34 billion cells (1.16 million metric tons), down from March's 1.71 billion cells (1.78 million tons) as buyers front-loaded purchases before the tax refund cancellation
• The 60% year-over-year increase likely understates actual growth in energy terms due to ongoing advances in photovoltaic technology
• Strong demand from Southeast Asia and Africa continues to drive export growth, with country-specific data to be released by China's customs administration on Wednesday

Merck announced that its experimental drug sacituzumab tirumotecan met primary endpoints in a late-stage trial for endometrial cancer, showing improved survival and delayed disease progression compared to chemotherapy. The trial enrolled 776 patients with advanced or recurrent endometrial cancer who had progressed despite standard treatments.

• The drug demonstrated both extended overall survival and delayed disease worsening versus chemotherapy in patients with cancer of the uterus lining
• Trial included 776 patients with advanced or recurrent endometrial cancer who had failed standard treatment options
• This positive late-stage trial result positions the drug as a potential new treatment option for a difficult-to-treat patient population

Commerzbank formally rejected UniCredit's takeover offer on May 18, 2026, escalating a cross-border battle that began in 2024 when the Italian bank started accumulating its stake in the German lender. Both Commerzbank's supervisory and management boards recommended shareholders reject the bid, citing inadequate valuation and significant risks.

• UniCredit has become Commerzbank's largest shareholder with a stake approaching 30% after beginning its accumulation in 2024
• Commerzbank criticized the offer as 'vague and coercive' with a 'quasi-nil premium' that does not reflect the bank's fundamental value
• The formal rejection is expected to prolong the takeover battle for one of Germany's top banks, marking months of resistance to the cross-border acquisition attempt